Trial Profile

A phase Ib/II study of ARQ 761 in patients selected for tumours with high levels of the biomarker NQ01

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ARQ 761 (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
Indications Pancreatic cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

14 Jun 2018 According to an ArQule media relerase,this trial is conducted in partnership with the University of Texas Southwestern Medical Center.
04 May 2016 According to an ArQule media release, the first cohort of patients has been enrolled in this trial.
04 May 2016 According to an ArQule media release, status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com